LABGENIUS
16.11.2022 09:01:48 CET | Business Wire | Press release
LabGenius, a pioneer in the use of machine learning (ML) for antibody-based drug discovery, today announced the appointment of Leonard Wossnig Ph.D. as Chief Technology Officer (CTO). In this role, Leonard will lead a team of Data Scientists, Software Engineers, and Automation Experts to further enhance LabGenius’ data-driven platform capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005063/en/
Dr. Leonard Wossnig, LabGenius CTO (Photo: Business Wire)
“Leonard is a brilliant addition to our team,” says LabGenius’ CEO and Founder, Dr. James Field. “His proven track record of implementing cutting-edge machine learning solutions for drug discovery programmes will supercharge our ability to deliver across multiple discovery projects.”
In 2018, Leonard co-founded Rahko, a leading quantum machine learning company whose technology platform combined computational chemistry, machine learning and quantum computing to drive a better understanding of drug behaviour. During his time as CEO, Leonard directed Rahko’s commercial and scientific strategy, which aimed to remove bottlenecks in drug discovery by applying quantum machine learning models to the identification and optimisation of potential drug candidates. Earlier this year, Rahko was acquired by Odyssey Therapeutics, where, as VP of AI, Leonard led a team of machine learning experts to develop a computational platform for generative drug design in the areas of cancer and inflammation.
Commenting on his appointment, Leonard said: “The ML-driven antibody-based platform that the team at LabGenius has built presents an opportunity to revolutionise today’s approach to drug discovery. Through the development of bespoke automated pipelines, the team is able to generate high-quality data at scale — this is a crucial precursor to the effective use of machine learning. With these solid foundations in place, I am excited to apply my experiences to help unlock the vast potential that computational methods have to accelerate the discovery of better medicines.”
Dr. Edwin Moses, LabGenius’ Chairman commented that “Leonard's appointment reinforces LabGenius’ commitment to technical excellence. His expertise in generative molecule design, paired with LabGenius’ cutting-edge drug discovery platform, is an excellent combination, which will further accelerate the company’s ability to discover uniquely powerful protein-based therapeutics.”
– end –
About LabGenius
Headquartered in London, LabGenius is a leading machine learning-driven protein engineering company. The company’s core technology platform, EVA™, enables the rapid discovery of novel therapeutic antibodies. LabGenius’ highly multidisciplinary team brings together the very best minds from the fields of computer science, robotic automation and synthetic biology.
For more information, please visit www.labgeni.us, or connect on Twitter, LinkedIn and Medium.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache19.11.2026 08:00:00 CET | Press release
Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far. A severe and difficult-to-treat neurological disorder Cluster headache is a severe neurological disorder characterised by recu
RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 07:00:00 CET | Press release
RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co
Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 07:00:00 CET | Press release
Pilot completed with DBS and Franklin Templeton via Ant’s WhaleRTP platformWhitepaper launched detailing Whale Orchestration Protocol framework and its development under BLOOM Field GuideSolution achieves Singapore’s first successful cross-asset interoperability between tokenised deposits and tokenised money market funds Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and token
NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 06:30:00 CET | Press release
NETS becomes the first national payment rail to join Ant International’s Agentic Mobile ProtocolNETS and Ant International’s MOU signing signals commitment to deepen the companies’ long-standing collaboration since 2023The partnership aims to deliver comprehensive AI-native merchant solutions to expand reach and lift operational efficiency Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explo
SBC Medical Group Reports Cybersecurity Incidents in Japan19.11.2026 05:39:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical Group" or the "Company"), a provider of comprehensive management services to medical corporations and their clinics, today reported the occurrence of recent cybersecurity incidents involving customer information associated with certain clinics in Japan, along with the status of its response. Overview of the Incidents On November 16, 2026, unauthorized access occurred to certain databases within a website system managed and operated by SBC Medical Group, Ltd., the Company’s, Japanese subsidiary, in connection with its management services in Japan. The Company confirmed that an unauthorized third party accessed and extracted customer information. The method of intrusion and full scope remain under investigation. Based on current information, the information obtained and the number of affected customers are as follows: Category Types of information Individuals Period Basic personal information (without reservation or trea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
